Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Bristol-Myers Squibb
AstraZeneca
Eisai Inc.
Novartis
PMV Pharmaceuticals, Inc
Mayo Clinic
Novartis
Kivu Bioscience Inc.
NeoImmuneTech
BeOne Medicines
Aktis Oncology, Inc.
Genmab
Exelixis
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Arcus Biosciences, Inc.
Sumitomo Pharma America, Inc.
Bristol-Myers Squibb
Genmab
Radiopharm Theranostics, Ltd
Seagen Inc.
Bayer
IntoCell, Inc
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Exscientia AI Limited
Eli Lilly and Company
NiKang Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
SystImmune Inc.
City of Hope Medical Center
Boundless Bio, Inc.
Eli Lilly and Company
Novartis
Radiopharm Theranostics, Ltd
Eli Lilly and Company
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Seagen Inc.
Innate Pharma
Novartis
I-Mab Biopharma US Limited
Compass Therapeutics
NeoTX Therapeutics Ltd.
Transgene
BicycleTx Limited
Bolt Biotherapeutics, Inc.